Log in

Xenetic Biosciences Stock Forecast, Price & News

+0.04 (+4.12 %)
(As of 11/27/2020 12:00 AM ET)
Today's Range
Now: $1.01
50-Day Range
MA: $0.89
52-Week Range
Now: $1.01
Volume306,664 shs
Average Volume394,920 shs
Market Capitalization$6.36 million
P/E RatioN/A
Dividend YieldN/A
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
Read More
Xenetic Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:XBIO



Sales & Book Value

Annual Sales$20,000.00
Book Value$2.84 per share


Net Income$-12,770,000.00


Market Cap$6.36 million
Next Earnings Date12/4/2020 (Estimated)
OptionableNot Optionable
+0.04 (+4.12 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive XBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for XBIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Xenetic Biosciences (NASDAQ:XBIO) Frequently Asked Questions

How has Xenetic Biosciences' stock price been impacted by COVID-19?

Xenetic Biosciences' stock was trading at $0.7031 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, XBIO stock has increased by 43.6% and is now trading at $1.01.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Xenetic Biosciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenetic Biosciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Xenetic Biosciences
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Xenetic Biosciences?

Wall Street analysts have given Xenetic Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Xenetic Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Xenetic Biosciences' next earnings date?

Xenetic Biosciences is scheduled to release its next quarterly earnings announcement on Friday, December 4th 2020.
View our earnings forecast for Xenetic Biosciences

How were Xenetic Biosciences' earnings last quarter?

Xenetic Biosciences Inc (NASDAQ:XBIO) released its earnings results on Thursday, May, 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.18. The company earned $0.06 million during the quarter.
View Xenetic Biosciences' earnings history

What price target have analysts set for XBIO?

2 brokers have issued 12-month target prices for Xenetic Biosciences' shares. Their forecasts range from $2.00 to $2.50. On average, they expect Xenetic Biosciences' stock price to reach $2.25 in the next year. This suggests a possible upside of 122.8% from the stock's current price.
View analysts' price targets for Xenetic Biosciences

Are investors shorting Xenetic Biosciences?

Xenetic Biosciences saw a increase in short interest in October. As of October 30th, there was short interest totaling 587,500 shares, an increase of 18.2% from the October 15th total of 497,200 shares. Based on an average daily volume of 236,400 shares, the short-interest ratio is currently 2.5 days. Approximately 11.0% of the company's stock are sold short.
View Xenetic Biosciences' Short Interest

Who are some of Xenetic Biosciences' key competitors?

What other stocks do shareholders of Xenetic Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenetic Biosciences investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Biocept (BIOC), Trevena (TRVN), TherapeuticsMD (TXMD), T2 Biosystems (TTOO), Vaxart (VXRT), Aytu BioScience (AYTU) and Co-Diagnostics (CODX).

Who are Xenetic Biosciences' key executives?

Xenetic Biosciences' management team includes the following people:
  • Mr. Jeffrey F. Eisenberg, CEO & Director (Age 53)
  • Mr. James F. Parslow, CFO, COO & Corp. Sec. (Age 54)
  • Dr. Curtis A. Lockshin, Chief Scientific Officer (Age 59)

What is Xenetic Biosciences' stock symbol?

Xenetic Biosciences trades on the NASDAQ under the ticker symbol "XBIO."

How do I buy shares of Xenetic Biosciences?

Shares of XBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Xenetic Biosciences' stock price today?

One share of XBIO stock can currently be purchased for approximately $1.01.

How big of a company is Xenetic Biosciences?

Xenetic Biosciences has a market capitalization of $6.36 million and generates $20,000.00 in revenue each year. Xenetic Biosciences employs 4 workers across the globe.

What is Xenetic Biosciences' official website?

The official website for Xenetic Biosciences is www.xeneticbio.com.

How can I contact Xenetic Biosciences?

Xenetic Biosciences' mailing address is 40 Speen Street Suite 102, Framingham MA, 01701. The company can be reached via phone at 781-778-7720 or via email at [email protected]

This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.